Thalys(SH:603716) Sou Hu Cai Jing·2026-01-28 07:57Core Viewpoint - The company currently does not have any Nipah virus-related testing reagents, instruments, or treatment drugs in its inventory, nor does it have any products for agency sales. The focus is on early identification and warning capabilities for high-risk acute infections through the Inflammatix TriVerity™ system, which can assist in early triage and monitoring for suspected cases of Nipah virus [1]. Group 1 - The company received an inquiry regarding its preparedness for the Nipah virus outbreak in West Bengal, India, which has affected several healthcare workers [1]. - The company confirmed that it does not possess any Nipah virus-related testing reagents or treatment options at this time [1]. - The company's strategic focus is on early identification and warning for high-risk acute infections, utilizing the Inflammatix TriVerity™ system for early infection type determination and risk stratification [1]. Group 2 - The Inflammatix TriVerity™ system can provide early warning and triage support in emergency settings for suspected cases, facilitating quicker diagnosis and treatment processes [1]. - The company emphasizes that while TriVerity™ can assist in early detection, final confirmation still requires pathogen detection methods [1].